Compare Adecoagro SA (AGRO) vs Novartis AG (NVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adecoagro SA vs Novartis AG — how do they compare? Adecoagro SA trades at $10.12 (market cap $1.39B), while Novartis AG trades at $155.54 (market cap $298.98B). The key difference: Novartis AG is far larger — about 215.1× Adecoagro SA's market cap, and Adecoagro SA pays the higher dividend (3.08%). Which is the better fit depends on your goals.
| AGRO | NVS | |
|---|---|---|
Market Cap | $1.39B | $298.98B |
Sector | Technology | Health |
52-Week High | $15.25 | $168.62 |
52-Week Low | $7.13 | $113.50 |
Enterprise Value | $3.42B | $339.00B |
Dividend Yield | 3.08% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
Novartis (NVS) trades at $157.03, down 1.79% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $56.67B revenue, 23.92% net margin, and robust cash flow generation. Recent developments include multiple strategic acquisitions and regulatory approvals expanding the oncology pipeline, though earnings have shown volatility with two misses in the last four quarters.
NVS presents a balanced investment case with strong profitability and pipeline expansion offset by valuation concerns and earnings inconsistency. The stock offers stability through defensive healthcare exposure but faces execution risks from integration challenges and competitive pressures in pharmaceutical markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
